BDSX Stock News & Analysis | Latest Updates

Biodesix Announces One-for-Twenty Reverse Stock Split

(NASDAQ:BDSX) LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to trade under Biodesix’s existing trading symbol, BDSX, on the Nasdaq Global Market (“Nasdaq”) on a split-adjusted basis when the market opens on Monday, September 15, 2025, with the new CUSIP number 09075X207.

September 11, 2025Stock Split

BDSX News

Biodesix Announces One-for-Twenty Reverse Stock Split

Biodesix Announces Second Quarter 2025 Results and Highlights

Bodesix Announced That It Is Partnering With The Association Of Pulmonary Advanced Practice Providers To Bring New Educational Programs Aimed At Their Professional Membership To Better Provide Access And Timely Care To Patients At Risk For Lung Cancer

Biodesix Has Been Granted European Patent Number EP3698144 Titled COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER.

Biodesix To Present New INSIGHT Study Data At ASCO 2025 Showing VeriStrat Test Predicts Improved Survival With Chemoimmunotherapy Over Immunotherapy Alone In PD-L1 ≥50% Metastatic NSCLC Patients With Poor Immune Classifier

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Scotiabank Maintains Sector Outperform on Biodesix, Lowers Price Target to $2

Biodesix Form4 Filing Shows Jack Schuler Bought 4,723,239 Shares Of Stock At An Average Price Of $0.28/Share

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Biodesix Highlights Urgent Need for Better Lung Nodule Diagnosis After Study of 350K U.S. Patients

Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Craig-Hallum Maintains Buy on Biodesix, Lowers Price Target to $1.5

Biodesix Analysts Lower Their Forecasts After Downbeat Q1 Results

Lake Street Maintains Buy on Biodesix, Lowers Price Target to $2

William Blair Downgrades Biodesix to Market Perform

Biodesix Lowers FY2025 Sales Guidance from $92.00M-$95.00M to $80.00M-$85.00M vs $92.93M Est

Canaccord Genuity Maintains Buy on Biodesix, Lowers Price Target to $2.5

12 Health Care Stocks Moving In Tuesday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

US Futures Tumble As Traders Await Trump's Congress Address: 'Volatility Is Certainly Being Fed By Trump 2.0 Moves,' Says Expert

Biodesix Q4 EPS $(0.06) Beats $(0.07) Estimate, Sales $20.43M Beat $19.88M Estimate

Biodesix Sees Q4 Revenues Of $20.4M And FY24 Revenues Of $71.3M Vs. $70.73M Estimate

Biodesix Files For Mixed Shelf Of $250M; Company Says It May Sell Any Combination Of These Securities In One Or More Offerings Directly Or To Or Through Underwriters Or Dealers, And Also To Other Purchasers Or Through Agents

Biodesix Reiterates 2024 Revenue Forecast Of Between $70M-$72M Vs. $71.21M Estimate

Biodesix Q3 2024 GAAP EPS $(0.07), Inline, Sales $18.151M Miss $18.611M Estimate